Urethritis

Introduction

Diagnosis

Non-gonoccal Urethritis

Causative Agents

Discharge Sampling

Antibiotics

Gonococcal vs Non-gonococcal

Gonococcal Urethritis

Recurrent Urethritis

Introduction

Urethritis represents one of the more common syndromes seen by the general medical officer. It consists of urethral discharge, dysuria, and evidence of a urethral polymorphonuclear leukocytosis. It implies urethral inflammation or infection and is usually sexually acquired.

Causative Agents

Urethritis is classified as either gonococcal urethritis (GCU) if caused by Neisseria gonorrhoeae, or as nongonococcal urethritis (NGU) if caused by other infectious etiologies. The term nongonococcal urethritis (NGU) is more appropriate than the older term nonspecific urethritis (NSU), since there are specific causes for NGU. Chlamydia trachomatis or Ureaplasma urealyticum are the most frequent causes of NGU. Postgonococcal urethritis (PGU) is nongonococcal urethritis occurring shortly after therapy for urethral gonorrhea and is usually due to Chlamydia trachomatis.

Gonococcal vs Non-gonococcal Urethritis

Nongonococcal urethritis occurs more frequently than gonococcal urethritis worldwide. Although the clinical spectrum of gonococcal urethritis and non-gonococcal urethritis differ, there is often so much overlap that any differentiation cannot be based reliably on clinical features alone. For example, dysuria and urethral discharge is common in both gonococcal and non-gonococcal urethritis. However, a thick, purulent discharge present at the meatus strongly suggests GCU, especially when spontaneous or copious. A clear or scant urethral discharge suggests NGU. The incubation period for gonorrhea is usually shorter than for non-gonococcal urethritis.

The majority of men with gonorrhea develop symptoms within 4 days, while those with NGU develop symptoms within 7 to 21 days. Gonorrhea may occur as an asymptomatic infection in 1 to 10 percent of the cases in men and in as many as 50 percent of the cases in women. Non-gonococcal urethritis may be asymptomatic in up to 25 percent of infected men (5-10 percent in young active duty men), and in over 50 percent of infected women.

Diagnosis of Urethritis

The diagnosis of urethritis should be based upon both a physical exam and microscopic assessment of the urethral material. It is preferable to examine the patient at least 2 hours after micturition or before their first morning void. The patient should provide a first morning void and the first 10 to 15 cc. of the urine is saved. It is centrifuged so that the sediment may be analyzed microscopically under high power or oil immersion field. The presence of 10 or more polymorphonuclear leukocytes seen under high power is suggestive of urethritis.

Discharge Sampling

Next, any discharge present at the meatus is easily recovered for examination. If a discharge is not present, the urethra should be gently stripped by placing the gloved thumb along the ventral surface of the penis with the fingers above, applying gentle pressure, and moving the thumb forward to deliver the discharge.

If no discharge is expressed from the meatus, urethral material must be recovered by inserting a small swab into the urethra. A calcium alginate or rayon swab on a metal shaft is recommended. Cotton swabs, particularly on wooden shafts, may be toxic to organisms such as chlamydia. The 1 to 2mm swab tip should be inserted approximately 1.5 to 2 inches into the urethra and then removed while being rotated.

Gonococcal Urethritis

A gram stain is prepared and a culture obtained for N. gonorrhoea, using selective media for gonorrhea (modified Thayer-Martin, or chocolate agar). The gram stain  is examined using the oil-immersion objective of the microscope. The presence of 4 or more polymorphonuclear leukocytes (PMNs) per oil immersion field is diagnostic for urethritis. The presence of gram-negative, intracellular diplococci on gram stain establishes a diagnosis of gonorrhea. If these organisms are not observed, the patient is said to have NGU. The presence of extracellular organisms having the same morphology has no diagnostic significance. The complete absence of PMNs argues against urethritis. This test is more than 95 percent accurate in men with symptomatic acute urethritis.

The diagnosis of gonorrhea from the gram stain  is usually confirmed by the culture. The growth of typical colonies that are oxidase positive and consist of gram-negative diplococci strongly suggests gonorrhea. However, a negative culture in the face of a positive gram stain does not rule out GCU.

Non-gonoccal Urethritis (NGU)

In contrast, the diagnosis of NGU requires the presence of urethritis in addition to an exclusion of urethral infection due to N. gonorrhoea. Chlamydia trachomatis causes 30 to 50 percent of cases of NGU in young adults. It is an obligate intracellular parasite that can only be grown in specialized tissue cells, not in routine culture medium. Coinfection with C. trachomatis and N. gonorrhoea is very common, occurring in 10 to 35 percent of men and in 40 to 60 percent of women, and has an effect on management strategies.

Antibiotics

There are many options in the treatment of gonococcal urethritis. A single dose of ceftriaxone (250 mg IM) will still reliably eradicate N. gonorrhoea from patients with uncomplicated infection. The 1 mL injection of ceftriaxone is less painful if reconstituted with 1% xylocaine.

Another option is Cefixime 400 mg orally once. This has a 97.1 percent cure rate.

Of the quinalones, Ofloxacin 400 mg orally, or Ciprofloxacin 500 mg orally once have 98.4 percent and 99.8 percent cure rates, respectively. Unfortunately in some parts of Asia widespread resistance has been noted.

Due to the high likelihood of coinfection with Chlymadia trachomatis, and to prevent the development of postgonococcal urethritis, it is recommended that in addition to the ceftriaxone for GCU, a second regimen should be included which is effective against Chlamydia. Again several options exist.

Doxycycline (100mg orally BID) for 7 days or Azithromycin 1 gram orally once are the preferred treatments.

Erythromycin (500mg base or EES 800 mg orally QID) for 7 days. Patients unable to tolerate this much Erythromycin can be given (250mg base or 400mg EES orally QID) extended to 14 days.

A final option is Ofloxacin 300mg BID orally for 7 days. While Azithromycin can be more expensive than Doxycycline, it has an advantage in that the complete treatment can be witnessed in the medical department. This may offset the expense of treatment failures for longer treatments. A critical part of the treatment is the recommendation that both men and women should abstain from sexual intercourse for 7 days after the start of therapy to prevent the spread of partially treated organisms.

Recurrent Urethritis

Persistence or recurrence of urethritis within 6 weeks of therapy occurs more commonly when NGU is not due to Chlamydia. The persistence of urethritis should be documented by observing PMNs on a urethral smear or urinalysis. Reinfection is the most common cause of recurrence. A careful sexual history regarding reexposure and adequate treatment of sexual partners is critical to the management of this condition. Careful evaluation for untreated sexual partners is essential. Once treatment failures, non-compliance, and re-exposure have been ruled out, a wet prep from the urethra should be examined for T. Vaginalis. Treatment should be with Metronidazole 2 grams orally once plus Erythromycin 500mg base or 800 mg EES orally QID for 7 days.

The absence of PMNs suggests resolution of the infectious process but with a persistent pain syndrome that does not require further treatment with antimicrobials. Generally, 15 to 30 percent of all persistent urethritis or dysuria is noninfectious and resolves within 6 months without therapy. Also, in this situation consider Herpes Simplex virus as a source.

Revised by LT Todd J. May, MC, USNR, U.S. Naval Hospital Okinawa, Okinawa Japan (1999). 

Preface  ·  Administrative Section  ·  Clinical Section

The General Medical Officer Manual , NAVMEDPUB 5134, January 1, 2000
Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This web version of The General Medical Officer Manual, NAVMEDPUB 5134 is provided by The Brookside Associates Medical Education Division.  It contains original contents from the official US Navy version, but has been reformatted for web access and includes advertising and links that were not present in the original version. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense. All material in this version is unclassified. This formatting © 2006 Medical Education Division, Brookside Associates, Ltd. All rights reserved.

Home  ·  Textbooks and Manuals  ·  Videos  ·  Lectures  ·  Distance Learning  ·  Training  ·  Operational Safety  ·  Search


This website is dedicated to the development and dissemination of medical information that may be useful to those who practice Operational Medicine. This website is privately-held and not connected to any governmental agency. The views expressed here are those of the authors, and unless otherwise noted, do not necessarily reflect the views of the Brookside Associates, Ltd., any governmental or private organizations. All writings, discussions, and publications on this website are unclassified.

© 2006 Medical Education Division, Brookside Associates, Ltd. All rights reserved

Other Brookside Products

Contact Us

Advertise on this Site